NEW YORK, July 2, 2026, 19:04 (EDT)
- Recursion ended the session at $3.80, gaining 3.54%, and then ticked to $3.79 after hours. Volume hit 32.65 million shares, about 194% of its 65-day average.
- Chris Gibson, a former director, filed a Form 144 on July 2 to sell 100,000 shares valued at $374,500. That’s about 0.3% of Thursday’s trading volume.
- RXRX had 184.02 million shares sold short as of June 15, or 39.11% of the float, according to the latest public data. The short-interest for June 30 comes out July 10.
Recursion Pharmaceuticals, Inc. NASDAQ:RXRX gained Thursday, even as the Nasdaq slipped. Shares climbed 4%, but the more telling move came from the numbers behind the trade. Founder sales filed Thursday were minor against the day’s volume, almost lost next to short interest still reported in the open data.
Shares of the Salt Lake City drug maker ended the day at $3.80, up 3.54%, with 32.65 million shares traded. After hours, the stock was quoted at $3.79 as of 6:34 p.m. EDT, MarketWatch showed.
There’s been no new clinical data from Recursion in the last two days, just ownership filings. The last release on the company’s press portal was June 2, and recent filings include a July 2 Form 144, two Form 4s on July 2, and another Form 144 on July 1.
Christopher Gibson, a former director, filed a Form 144 on July 2. Recursion said in April that founder Gibson would keep his board seat through June 2026 and stay on as a strategic adviser.
| Filing item | Size | Investor read |
|---|---|---|
| Gibson’s July 2 planned sale | 100,000 shares; $374,500 total market value | Makes up 0.019% of 524.7 million shares on file, and around 0.3% of Thursday’s traded volume. |
| Gibson’s prior three months of listed sales | 640,440 shares; $2.13 million gross proceeds | Add in the proposed sale and Gibson’s total since early April comes to 740,440 shares, about $2.50 million. |
| Form 4s for directors filed July 2 | Zavain Dar got 5,109 shares at $0; Dean Li got 3,747 shares at $0 | Both directors got these shares under the comp policy for outside board members, not through open-market purchases. |
Form 144 is a notice of a planned sale. According to Investor.gov, affiliates file it when they plan to sell more than 5,000 shares or $50,000 under Rule 144 in three months. The form means the filer says they really intend to sell soon.
Short interest is high. WSJ data put 184.02 million shares sold short as of June 15, or 39.11% of float. That’s 5.6 times Thursday’s total volume, which means even a big up day wouldn’t mean shorts have covered.
That’s important since the latest short interest data hasn’t been released. According to FINRA’s calendar, the report for the June 30 settlement is scheduled for 6 p.m. Eastern on July 2, and should be published July 10. So investors heading into the holiday break only have the June 15 numbers to go on.
| Instrument | Latest cited move | Thursday read |
|---|---|---|
| Recursion Pharmaceuticals NASDAQ:RXRX | Closed at $3.80, up 3.54%; moved to $3.79 after hours | Unusual volume hit the stock. |
| SPDR S&P Biotech ETF (NYSEARCA:XBI) | $160.46, up 2.49% | Biotech space got lifted, but Recursion was stronger. |
| iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) | $195.70, up 2.95% | Big biotech names traded steady. |
| Invesco QQQ Trust NASDAQ:QQQ | $712.60, down 1.70% | Tech-growth proxy came off. |
| SPDR S&P 500 ETF (NYSEARCA:SPY) | $744.78, off 0.11% | Wider market ended flat to lower. |
The main story is still about cash burn and clinical timing. Recursion had $665.2 million in cash, cash equivalents and restricted cash at March 31. Net loss for the first quarter was $117.5 million. Net cash used in operations was $81.1 million. The company said its cash runway goes into early 2028.
CEO Najat Khan told investors on the May earnings call that the fully owned pipeline is set for “multiple clinical readouts over the next 12 to 18 months.” CFO Ben Taylor said Recursion would stick to “cash operating expense guidance of less than $390 million.” The Motley Fool
Nasdaq’s regular session had finished at the time of the dateline. The exchange’s listed trading hours are 9:30 a.m. through 4 p.m. Eastern, while after-hours run until 8 p.m. Nasdaq said it will be closed July 3, 2026, for Independence Day observed.
